Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott North

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Investigational New Drugs|August 28, 2016
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)Sunil Parimi, Misha Eliasziw, Scott North, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
Cancer|July 15, 2017
Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trialScott C Adams, Darren S DeLorey, Margie H Davenport, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 10, 2013
Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral ProcessJo-An Seah, Normand Blais, Scott North, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 27, 2019
Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of CanadaZineb Hamilou, Scott North, Christina Canil, et al.
Urologic Oncology|May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancerEric Winquist, Malcolm J Moore, Kim N Chi, et al.
The Journal of Urology|November 16, 2010
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapyToni K Choueiri, Wanling Xie, Christian Kollmannsberger, et al.
Clinical Genitourinary Cancer|May 21, 2013
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortiumMichael M Vickers, Hulayel Al-Harbi, Toni K Choueiri, et al.
Therapeutic Advances in Medical Oncology|May 6, 2022
The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapyHusam A Alqaisi, Carlos Stecca, Zachary W Veitch, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 updateFred Saad, Sebastien Hotte, Charles Catton, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Investigational New Drugs|August 28, 2016
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)Sunil Parimi, Misha Eliasziw, Scott North, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
Cancer|July 15, 2017
Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trialScott C Adams, Darren S DeLorey, Margie H Davenport, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 10, 2013
Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral ProcessJo-An Seah, Normand Blais, Scott North, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 27, 2019
Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of CanadaZineb Hamilou, Scott North, Christina Canil, et al.
Urologic Oncology|May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancerEric Winquist, Malcolm J Moore, Kim N Chi, et al.
The Journal of Urology|November 16, 2010
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapyToni K Choueiri, Wanling Xie, Christian Kollmannsberger, et al.
Clinical Genitourinary Cancer|May 21, 2013
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortiumMichael M Vickers, Hulayel Al-Harbi, Toni K Choueiri, et al.
Therapeutic Advances in Medical Oncology|May 6, 2022
The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapyHusam A Alqaisi, Carlos Stecca, Zachary W Veitch, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 updateFred Saad, Sebastien Hotte, Charles Catton, et al.
Pageof 10